Zhaoke Ophthalmology Ltd
Company Profile
Business description
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
Contact
No. 1 Meide 3rd Road
Pearl River Industrial Park
Nansha District
Guangdong Province
Guangzhou
CHNT: +86 2039062828
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
276
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
stocks
ASX listed media giant drives strong earnings growth
stocks
ASX real estate platform outperforms yet questions remain
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,726.03 | 11.10 | 0.13% |
| DAX 40 | 26,355.07 | 35.62 | 0.14% |
| Dow JONES (US) | 53,968.26 | 68.67 | -0.13% |
| FTSE 100 | 10,862.50 | 38.59 | -0.35% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,640.68 | 49.94 | -0.19% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,761.65 | 4.01 | 0.05% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |